Understanding Perry Syndrome
At a Glance
Perry syndrome is a rare inherited brain disease caused by a harmful change in the DCTN1 gene. It can cause parkinsonism, depression or apathy, weight loss, and reduced breathing during sleep, making coordinated neurologic, respiratory, and nutritional care essential.
Caring for someone with Perry syndrome—or navigating it yourself—can feel like navigating an unknown landscape. Because this condition is ultra-rare—meaning very few doctors have ever encountered a case in person—you may have already faced a long and frustrating search for answers [1]. This guide is designed to help you understand the biology of this condition and give you the tools to coordinate a care team that truly understands its unique challenges.
What is Perry Syndrome?
Perry syndrome is a rare, autosomal dominant neurodegenerative disease [1]. “Autosomal dominant” means that a person only needs to inherit one copy of a pathogenic variant (a mutated gene) to develop the condition. It is a progressive illness that affects several different systems of the body simultaneously, often beginning in middle age [1][2].
The journey to a diagnosis often involves recognizing four “cardinal” or main features that define the condition, sometimes referred to as the classic tetrad [1]. Keep in mind that these symptoms may be absent, mild, or appear years apart in a diagnosed person.
The Characteristic Features
While every person’s experience is unique, Perry syndrome is known for four major features that help doctors distinguish it from more common conditions like Parkinson’s disease [1][3].
- Parkinsonism: This involves motor symptoms such as slowness of movement (bradykinesia), stiffness or rigidity in the limbs, and sometimes tremors [3]. Unlike typical Parkinson’s, these symptoms often affect both sides of the body equally from the start and may progress more quickly [3].
- Psychiatric Changes: Severe depression or apathy (a profound lack of interest, emotion, or motivation) are often among the first signs of the condition [3][4]. These are not just reactions to being ill; they are direct results of the disease affecting the brain’s emotional centers.
- Weight Loss: Significant, unexplained weight loss is common [1]. This can happen even if the person seems to be eating normally, though it can eventually be complicated by dysphagia (difficulty swallowing) [5].
- Central Hypoventilation: This is perhaps the most critical symptom to monitor. Unlike typical snoring or sleep apnea where the airway is blocked, central hypoventilation occurs because the brain “forgets” to tell the lungs to breathe deeply or often enough, especially during sleep [3][6].
The Genetic Cause: The DCTN1 Gene
At the heart of Perry syndrome is a pathogenic variant in the DCTN1 gene [1]. This gene provides instructions for making a protein called p150glued, which is one subunit of the dynactin complex [7].
To understand why this causes such widespread symptoms, it helps to think of the brain’s nerve cells (neurons) as a massive shipping and receiving network:
- The Highway: Neurons use long tubes called microtubules as tracks to move nutrients and waste back and forth.
- The Engine: A motor protein called dynein acts like a truck that carries cargo along these tracks.
- The Hitch: The dynactin complex (which includes p150glued) is the “hitch” that connects the cargo to the truck [7].
In Perry syndrome, the “hitch” is broken. This prevents essential materials from reaching the ends of the nerves and keeps waste products from being cleared away [7][8]. This breakdown in cellular transport is associated with the buildup of a protein called TDP-43 [9]. While the exact mechanism remains under study, TDP-43 clumps together in the wrong places, which is thought to contribute to nerve cells stopping working and eventually dying [9][10].
Why This Knowledge Matters
Currently, no established treatment stops the underlying neurodegeneration, meaning care is focused entirely on symptom management and support [11]. Because Perry syndrome affects the brain’s ability to control breathing, movement, and mood, you will likely need a diverse team of specialists. Local neurologists may focus heavily on the motor symptoms (the parkinsonism), but you must advocate for the other two critical pillars of care:
- Respiratory Care: Because breathing issues (hypoventilation) are the most serious risk, involve a pulmonologist early to discuss sleep studies and the potential use of non-invasive ventilation [3][11].
- Nutritional and Mood Support: Proactive weight monitoring and treatment for apathy or depression are essential for maintaining quality of life [11][12].
Because this disease is so rare, you and your loved one may become the most knowledgeable people in the room about your specific symptoms. This guide is your foundation for ensuring that every doctor you see understands that Perry syndrome is more than just a movement disorder—it is a complex condition that requires a watchful, multi-system approach [1].
Common questions in this guide
What are the main symptoms of Perry syndrome?
What causes Perry syndrome, and is it inherited?
Why is breathing during sleep a major concern in Perry syndrome?
How is Perry syndrome different from typical Parkinson’s disease?
Is there a treatment that stops Perry syndrome?
Why do people with Perry syndrome need several specialists?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Key features
Could my doctor check whether I have any of the four characteristic features?
Genetics and testing
Would DCTN1 genetic testing be useful for me, and what would it tell us?
Symptom support
What symptom management and support would my care team recommend for me?
Get notified when new evidence is published on Perry syndrome.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (12)
- 1
Establishing diagnostic criteria for Perry syndrome.
Mishima T, Fujioka S, Tomiyama H, et al.
Journal of neurology, neurosurgery, and psychiatry 2018; (89(5)):482-487 doi:10.1136/jnnp-2017-316864.
PMID: 29089398 - 2
DCTN1-related Parkinson-plus disorder (Perry syndrome).
Richardson D, McEntagart MM, Isaacs JD
Practical neurology 2020; (20(4)):317-319 doi:10.1136/practneurol-2020-002505.
PMID: 32434902 - 3
Clinical, pathological and genetic characteristics of Perry disease-new cases and literature review.
Dulski J, Cerquera-Cleves C, Milanowski L, et al.
European journal of neurology 2021; (28(12)):4010-4021 doi:10.1111/ene.15048.
PMID: 34342072 - 4
Cognitive and behavioral profile of Perry syndrome in two families.
Milanowski Ł, Sitek EJ, Dulski J, et al.
Parkinsonism & related disorders 2020; (77()):114-120 doi:10.1016/j.parkreldis.2020.05.019.
PMID: 32717578 - 5
Dysphagia in Perry Syndrome: Pharyngeal Pressure in Two Cases.
Umemoto G, Tsuboi Y, Furuya H, et al.
Case reports in neurology 2017; (9(2)):161-167 doi:10.1159/000457900.
PMID: 28690533 - 6
Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy.
Mishima T, Kasanuki K, Koga S, et al.
Parkinsonism & related disorders 2017; (42()):85-89 doi:10.1016/j.parkreldis.2017.06.003.
PMID: 28651750 - 7
DCTN1 Binds to TDP-43 and Regulates TDP-43 Aggregation.
Deshimaru M, Kinoshita-Kawada M, Kubota K, et al.
International journal of molecular sciences 2021; (22(8)) doi:10.3390/ijms22083985.
PMID: 33924373 - 8
Deficiency of Perry syndrome-associated p150Glued in midbrain dopaminergic neurons leads to progressive neurodegeneration and endoplasmic reticulum abnormalities.
Yu J, Yang X, Zheng J, et al.
NPJ Parkinson's disease 2023; (9(1)):35 doi:10.1038/s41531-023-00478-0.
PMID: 36879021 - 9
Perry Syndrome: A Distinctive Type of TDP-43 Proteinopathy.
Mishima T, Koga S, Lin WL, et al.
Journal of neuropathology and experimental neurology 2017; (76(8)):676-682 doi:10.1093/jnen/nlx049.
PMID: 28789478 - 10
TDP-43 Cryptic RNAs in Perry Syndrome: Differences across Brain Regions and TDP-43 Proteinopathies.
Pickles SR, Gonzalez Bejarano J, Narayan A, et al.
Movement disorders : official journal of the Movement Disorder Society 2025; (40(4)):662-671 doi:10.1002/mds.30104.
PMID: 39788898 - 11
Current advances in the clinical management of Perry syndrome: is there hope for the future?
Chmiela T, Wszolek ZK
Expert review of neurotherapeutics 2026; (26(2)):165-173 doi:10.1080/14737175.2025.2602031.
PMID: 41378835 - 12
Multifactorial anticholinergic toxicity-like presentation and malignant parkinsonism in Perry syndrome.
Takezaki Y, Iriki Y, Madokoro Y, et al.
Parkinsonism & related disorders 2026; (146()):108287 doi:10.1016/j.parkreldis.2026.108287.
PMID: 41864034
This page explains Perry syndrome for informational purposes only and does not constitute medical advice. A neurologist and other specialists should interpret symptoms and plan care for each person.